Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.

Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis.

Abdel Shaheed C, Carland JE, Graham GG, Stocker SL, Smith G, Hicks M, Williams KM, Furlong T, MacDonald P, Greenfield JR, Smith FC, Chowdhury G, Day RO.

Br J Clin Pharmacol. 2019 Aug 31. doi: 10.1111/bcp.14107. [Epub ahead of print]

PMID:
31471973
2.

Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection.

Kamel B, Williams KM, Graham GG, Norris RLG, Stocker SL, Carland JE, Pile KD, Day RO.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 15;1126-1127:121764. doi: 10.1016/j.jchromb.2019.121764. Epub 2019 Aug 14.

PMID:
31454721
3.

Comparison of the Area-Under-The-Curve for Vancomycin Estimated Using Compartmental and Non-compartmental Methods in Adult Patients with Normal Renal Function.

Shingde RV, Graham GG, Reuter SE, Carland JE, Day RO, Stocker SL.

Ther Drug Monit. 2019 Aug 16. doi: 10.1097/FTD.0000000000000690. [Epub ahead of print]

PMID:
31425492
4.

Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance.

Tay E, Sotiriou A, Graham GG, Wilhelm K, Snowden L, Day RO.

Ther Adv Psychopharmacol. 2019 Mar 29;9:2045125319836889. doi: 10.1177/2045125319836889. eCollection 2019. Review.

5.

Comment on ''Massive' metformin overdose' by Chiew et al.

Graham GG.

Br J Clin Pharmacol. 2018 Dec;84(12):2938-2939. doi: 10.1111/bcp.13723. Epub 2018 Sep 12. No abstract available.

PMID:
30209823
6.

Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.

Graham GG, Stocker SL, Kannangara DRW, Day RO.

Curr Rheumatol Rep. 2018 Jun 21;20(8):47. doi: 10.1007/s11926-018-0760-2. Review.

PMID:
29931553
7.

A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function.

Duong JK, Kroonen MYAM, Kumar SS, Heerspink HL, Kirkpatrick CM, Graham GG, Williams KM, Day RO.

Eur J Clin Pharmacol. 2017 Aug;73(8):981-990. doi: 10.1007/s00228-017-2251-1. Epub 2017 Apr 28.

PMID:
28451709
8.

Individualising the dose of allopurinol in patients with gout.

Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO.

Br J Clin Pharmacol. 2017 Sep;83(9):2015-2026. doi: 10.1111/bcp.13307. Epub 2017 May 28.

9.

Biosimilars approved for treatment of inflammatory rheumatological diseases.

Mahler SM, Wardiana A, Jones ML, de Bakker CJ, Graham GG, Howard CB.

Int J Rheum Dis. 2016 Nov;19(11):1043-1048. doi: 10.1111/1756-185X.13037. No abstract available.

PMID:
28032957
10.

Allopurinol: insights from studies of dose-response relationships.

Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):449-462. doi: 10.1080/17425255.2017.1269745. Epub 2016 Dec 20. Review.

PMID:
27927043
11.

Xanthine oxidoreductase and its inhibitors: relevance for gout.

Day RO, Kamel B, Kannangara DR, Williams KM, Graham GG.

Clin Sci (Lond). 2016 Dec 1;130(23):2167-2180. Review.

PMID:
27798228
12.

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

Kamel B, Graham GG, Williams KM, Pile KD, Day RO.

Clin Pharmacokinet. 2017 May;56(5):459-475. doi: 10.1007/s40262-016-0466-4. Review.

PMID:
27753003
13.

Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration.

Smith FC, Kumar SS, Furlong TJ, Gangaram SV, Greenfield JR, Stocker SL, Graham GG, Williams KM, Day RO.

Am J Kidney Dis. 2016 Dec;68(6):990-992. doi: 10.1053/j.ajkd.2016.08.017. Epub 2016 Oct 15. No abstract available.

PMID:
27751611
14.

Could metformin be used in patients with advanced chronic kidney disease?

Kumar SS, Graham GG, Smith FC, Furlong TJ, Greenfield JR, Stocker SS, Carland JE, Day RO.

Diabetes Obes Metab. 2017 Feb;19(2):302-303. doi: 10.1111/dom.12806. Epub 2016 Nov 9. No abstract available.

PMID:
27735109
15.

Trends in metformin utilisation and dose appropriateness in Australia.

Moon J, Kumar SS, Graham GG, Baysari MT, Williams KM, Chen W, Viardot A, Greenfield JR, Day RO.

Eur J Clin Pharmacol. 2016 Dec;72(12):1489-1496. Epub 2016 Aug 27.

PMID:
27568311
16.

Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate.

Kannangara DR, Phipps-Green AJ, Dalbeth N, Stamp LK, Williams KM, Graham GG, Day RO, Merriman TR.

Ann Rheum Dis. 2016 Jul;75(7):1363-6. doi: 10.1136/annrheumdis-2015-208111. Epub 2015 Dec 1.

PMID:
26835700
17.

Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine.

Kannangara DR, Graham GG, Williams KM, Day RO.

Clin Rheumatol. 2016 Sep;35(9):2375-6. doi: 10.1007/s10067-015-3165-x. Epub 2016 Jan 7. No abstract available.

PMID:
26742757
18.

Multiple episodes of aspirin overdose in an individual patient: a case report.

Ghosh D, Williams KM, Graham GG, Nair P, Buscher H, Day RO.

J Med Case Rep. 2014 Nov 19;8:374. doi: 10.1186/1752-1947-8-374.

19.

The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus.

Duong JK, Kumar SS, Furlong TJ, Kirkpatrick CM, Graham GG, Greenfield JR, Williams KM, Day RO.

Br J Clin Pharmacol. 2015 Apr;79(4):617-23. doi: 10.1111/bcp.12525.

20.

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.

Chung WH, Chang WC, Stocker SL, Juo CG, Graham GG, Lee MH, Williams KM, Tian YC, Juan KC, Jan Wu YJ, Yang CH, Chang CJ, Lin YJ, Day RO, Hung SI.

Ann Rheum Dis. 2015 Dec;74(12):2157-64. doi: 10.1136/annrheumdis-2014-205577. Epub 2014 Aug 12.

PMID:
25115449
21.

An audit of a therapeutic drug monitoring service for allopurinol therapy.

Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO.

Ther Drug Monit. 2013 Dec;35(6):863-6. doi: 10.1097/FTD.0b013e318299920a.

PMID:
24263644
22.

Republished research: non-steroidal anti-inflammatory drugs (NSAIDs).

Day RO, Graham GG.

Br J Sports Med. 2013 Nov;47(17):1127. doi: 10.1136/bjsports-2013-f3195rep. No abstract available.

PMID:
24159094
23.

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, Graham GG, Williams KM, Day RO.

Drug Saf. 2013 Oct;36(10):953-80. doi: 10.1007/s40264-013-0084-0. Review.

PMID:
23873481
24.

Hypouricemic effects of prednisone and allopurinol: an uneven playing field?

Kannangara DR, Graham GG, Williams KM, Day RO.

Can J Cardiol. 2014 Mar;30(3):376.e1. doi: 10.1016/j.cjca.2013.04.015. Epub 2013 Jul 4. No abstract available.

PMID:
23831009
25.

Non-steroidal anti-inflammatory drugs (NSAIDs).

Day RO, Graham GG.

BMJ. 2013 Jun 11;346:f3195. doi: 10.1136/bmj.f3195. No abstract available. Erratum in: BMJ. 2013;347:f4310.

PMID:
23757736
26.

The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.

Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF.

Inflammopharmacology. 2013 Jun;21(3):201-32. doi: 10.1007/s10787-013-0172-x. Epub 2013 May 30. Review.

PMID:
23719833
27.

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO.

Br J Clin Pharmacol. 2013 Dec;76(6):932-8. doi: 10.1111/bcp.12126.

28.

The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis.

Duong JK, Furlong TJ, Roberts DM, Graham GG, Greenfield JR, Williams KM, Day RO.

Drug Saf. 2013 Sep;36(9):733-46. doi: 10.1007/s40264-013-0038-6.

PMID:
23549904
29.

Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.

Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, Timmins P, Graham GG, Furlong TJ, Greenfield JR, Williams KM, Day RO.

Clin Pharmacokinet. 2013 May;52(5):373-84. doi: 10.1007/s40262-013-0046-9.

PMID:
23475568
30.

Comparing dose prediction software used to manage gentamicin dosing.

Wong C, Kumar SS, Graham GG, Begg EJ, Chin PK, Brett J, Ray JE, Marriott DJ, Williams KM, Day RO.

Intern Med J. 2013 May;43(5):519-25. doi: 10.1111/imj.12067.

PMID:
23279297
31.

Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients.

Brett J, Chong O, Graham GG, Ray JE, Marriott D, Williams KM, Day RO.

Ther Drug Monit. 2013 Feb;35(1):133-6. doi: 10.1097/FTD.0b013e318275fe69.

PMID:
23188182
32.

Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.

Kannangara DR, Ramasamy SN, Indraratna PL, Stocker SL, Graham GG, Jones G, Portek I, Williams KM, Day RO.

Arthritis Res Ther. 2012 Aug 17;14(4):R189. doi: 10.1186/ar4020.

33.

Metformin therapy in patients with chronic kidney disease.

Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM, Graham GG, Williams KM, Day RO.

Diabetes Obes Metab. 2012 Oct;14(10):963-5. doi: 10.1111/j.1463-1326.2012.01617.x. Epub 2012 May 27.

PMID:
22564555
34.

The pharmacokinetics of oxypurinol in people with gout.

Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO.

Br J Clin Pharmacol. 2012 Sep;74(3):477-89. doi: 10.1111/j.1365-2125.2012.04207.x.

35.

Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.

Kannangara DR, Roberts DM, Furlong TJ, Graham GG, Williams KM, Day RO.

Br J Clin Pharmacol. 2012 May;73(5):828-9. doi: 10.1111/j.1365-2125.2011.04147.x. No abstract available.

36.

Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?

Lee MH, Stocker SL, Anderson J, Phillips EJ, Nolan D, Williams KM, Graham GG, Sullivan JR, Day RO.

Intern Med J. 2012 Apr;42(4):411-6. doi: 10.1111/j.1445-5994.2011.02567.x.

PMID:
21790926
37.

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.

Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO.

J Rheumatol. 2011 May;38(5):904-10. doi: 10.3899/jrheum.101160. Epub 2011 Feb 1.

PMID:
21285173
38.

Clinical pharmacokinetics of metformin.

Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM.

Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000. Review.

PMID:
21241070
39.

Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.

Ng DY, Stocker SL, Graham GG, Williams KM, Day RO.

Eur J Clin Pharmacol. 2011 Jul;67(7):709-13. doi: 10.1007/s00228-010-0963-6. Epub 2010 Dec 23.

PMID:
21181139
40.

A proposal for identifying the low renal uric acid clearance phenotype.

Indraratna PL, Stocker SL, Williams KM, Graham GG, Jones G, Day RO.

Arthritis Res Ther. 2010;12(6):149. doi: 10.1186/ar3191. Epub 2010 Dec 16.

41.

A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism.

Bryant KJ, Bidgood MJ, Lei PW, Taberner M, Salom C, Kumar V, Lee L, Church WB, Courtenay B, Smart BP, Gelb MH, Cahill MA, Graham GG, McNeil HP, Scott KF.

J Biol Chem. 2011 Jan 28;286(4):2492-503. doi: 10.1074/jbc.M110.123927. Epub 2010 Nov 10.

42.

Emerging roles for phospholipase A2 enzymes in cancer.

Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, de Souza P, Dong Q, Graham GG, Russell PJ.

Biochimie. 2010 Jun;92(6):601-10. doi: 10.1016/j.biochi.2010.03.019. Epub 2010 Mar 31. Review.

PMID:
20362028
43.

FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?

Graham GG, Day RO, Graudins A, Mohamudally A.

Inflammopharmacology. 2010 Apr;18(2):47-55. doi: 10.1007/s10787-010-0036-6. Epub 2010 Mar 7. Erratum in: Inflammopharmacology. 2010 Apr;18(2):57.

PMID:
20213329
44.

Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations.

Koelsch M, Mallak R, Graham GG, Kajer T, Milligan MK, Nguyen LQ, Newsham DW, Keh JS, Kettle AJ, Scott KF, Ziegler JB, Pattison DI, Fu S, Hawkins CL, Rees MD, Davies MJ.

Biochem Pharmacol. 2010 Apr 15;79(8):1156-64. doi: 10.1016/j.bcp.2009.11.024. Epub 2009 Dec 5.

PMID:
19968966
45.

Hyperuricemia, cardiovascular disease, and the metabolic syndrome.

Indraratna PL, Williams KM, Graham GG, Day RO.

J Rheumatol. 2009 Dec;36(12):2842-3; author reply 2844. doi: 10.3899/jrheum.090500. No abstract available.

PMID:
19966196
46.
47.

Aurocyanide, dicyano-aurate (I), a pharmacologically active metabolite of medicinal gold complexes.

Graham GG, Whitehouse MW, Bushell GR.

Inflammopharmacology. 2008 Jun;16(3):126-32. doi: 10.1007/s10787-007-0020-y.

PMID:
18521543
48.

Utilization of allopurinol in the Australian community.

Chung Y, Lu CY, Graham GG, Mant A, Day RO.

Intern Med J. 2008 Jun;38(6):388-95. doi: 10.1111/j.1445-5994.2008.01641.x. Epub 2008 Apr 14.

PMID:
18422564
49.

Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy.

Chung Y, Stocker SL, Graham GG, Day RO.

Am J Med Sci. 2008 Mar;335(3):219-26. doi: 10.1097/MAJ.0b013e31815acb10. Review.

PMID:
18344696
50.

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO.

Clin Pharmacokinet. 2008;47(2):111-8.

PMID:
18193917

Supplemental Content

Loading ...
Support Center